New proposals for testing drugs with IKr-blocking activity to determine their teratogenic potential

Current Pharmaceutical Design

Volumn 13, Issue 29, 2007, Pages 2979-2988

  Karlsson, Miriam ^a   Danielsson, Bengt R ^a   Nilsson, Mats F ^a   Danielsson, Christian ^b   Webster, William S ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Almokalant; Antidepressant; Dofetilide; Drugs; Mice gestational days; Non selective monoamine reuptake inhibitors; Teratogenicity

Indexed keywords

ALMOKALANT; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CETIRIZINE; CISAPRIDE; CITALOPRAM; CLOMIPRAMINE; DOFETILIDE; FLUOXETINE; GREPAFLOXACIN; IBUTILIDE; IMIPRAMINE; MACROLIDE; MONOAMINE OXIDASE INHIBITOR; MOSAPRIDE CITRATE; NEUROLEPTIC AGENT; NEW DRUG; PIMONIDAZOLE; POTASSIUM CHANNEL BLOCKING AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TERFENADINE; UNINDEXED DRUG; VENLAFAXINE;

ANTIARRHYTHMIC ACTIVITY; BIRTH DEFECT; BRADYCARDIA; BREEDING; CONGENITAL MALFORMATION; DRUG EXPOSURE; DRUG MEGADOSE; DRUG OVERDOSE; DRUG WITHDRAWAL; EMBRYO CULTURE; EMBRYO DEATH; EMBRYOTOXICITY; ENTEROPATHY; FETOTOXICITY; FETUS MALFORMATION; GESTATION PERIOD; HEART ARRHYTHMIA; HUMAN; LOW DRUG DOSE; MATERNAL MORTALITY; NIDATION; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; QT PROLONGATION; REPEATED DRUG DOSE; REPRODUCTIVE TOXICITY; REVIEW; SINGLE DRUG DOSE; TERATOGEN TESTING; TERATOGENICITY; TOXICITY TESTING;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PREGNANCY; TERATOGENS;

EID: 36049032255     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207782110471     Document Type: Review

References (87)

1. Food and Drug Administration. Guidelines for reproduction studies for safety evaluation of drugs for human use. Washington, DC, FDA 1988; 5pp.
2. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58: 32-45.
3. ICH S7B Guideline. The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. European Medicines Agency. November 2005. http://www.emea.eu.intl/pdfs/human/ich/042302en.pdf (July 3, 2007).
4. ICH E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. US Food and Drug Administration, Centre for Drug Administration and Research. Oct 2005. http://www.fda.gov/cher/gdlns/iche14qtc.htm (July 3, 2007).
5. Tikosyn (dofetilide) pharmacological review part II. US FDA website. http:/www.fda.gov/cder/foi/nda/99/20-931_Tikosyn_pharmr_P2.pdf (July 3, 2007).
6. Spence SG, Vetter C, Hoe CM. Effects of the class III antiarrhythmic, dofetilide (UK-68,798) on the heart rate of midgestation rat embryos, in vitro. Teratology 1994; 49: 282-92.
7. Webster WS, Brown-Woodman PD, Snow MD, Danielsson BR. Teratogenic potential of almokalant, dofetilide, and d-sotalol: Drugs with potassium channel blocking activity. Teratology 1996; 53: 168-75.
8. Skold AC, Danielsson BR. Developmental toxicity of the class III antiarrhythmic agent almokalant in mice. Adverse effects mediated via induction of embryonic heart rhythm abnormalities. Arzneimittel-Forschung 2000; 50: 520-5.
9. Skold AC, Wellfelt K, Danielsson BR. Stage-specific skeletal and visceral defects of the I(Kr)-blocker almokalant: Finther evidence for teratogenicity via a hypoxia-related mechanism. Teratology 2001; 64: 292-300.
10. Naccarelli GV, Lee KS, Gibson JK, VanderLugt J. Electrophysiology and pharmacology of ibutilide. Am J Cardiol 1996; 78: 12-6.
11. Marks TA, Terry RD. Developmental toxicity of ibutilide fumarate in rats after oral administration. Teratology 1996; 54: 157-64
12. RxList Ibutilide http://www.rxlist.com/cgi/generic3/ ibutilide_wep.htm (July 3, 2007).
13. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 1997, 35: 13-29.
14. RxList Cordarone http://www.rxlist.com/cgi/generic/amiodarone cp.htm#W (July 3,2007).
15. Cordarone Amiodarone Hydrochloride Pharmacology Review (s). http://www.fda.gov/cder/foi/nda/pre96/ 18-972_Cardarone_Pharmr.pdf (July 3, 2007).
16. Abrahamsson C, Palmer M, Ljung B, Duker G, Baarnhielm C, Carlsson L, et al. Induction of thythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant. Cardiovase Res 1994; 28: 337-44.
17. Danielsson BR, Skold AC, Johansson A, Dillner B. Blomgren B, Teratogenicity by the hERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxiarelated mechanism mediated via embryonic arrhythmia. Toxicol Appl Pharmacol 2003; 193: 168-76.
18. Webster WS, Howe AM, Abela D, Oakes DJ. The relationship between cleft lip, maxillary hypoplasia, hypoxia and phenytoin. Curr Pharm Des 2006; 12: 1431-48.
19. Abela D. Hypoxia, Ikr-blocking drugs and embryonic development, PhD thesis University of Sydney to be completed 2008.
20. Chemoff N, Grabowski CT. Responses of the rat foetus to maternal injections of adrenaline and Vasopressin. Br J Pharmacol 1971; 43: 270-8.
21. Leist KH, Grauwiler J Fetal pathology in rats following uterine vessel clamping on day 14 of gestation. Teratology 1974; 10: 55-66.
22. Webster WS, Lipson AH, Brown-Woodman PDC. Uterine trauma and limb defects. Teratology 1987; 35: 253-69.
23. Webster WS, Brown-Woodman PDC. Cocaine as a cause of congenital malformations of vascular origin: Experimental evidence in the rat. Teratology 1990; 41: 689-97.
24. Danielson MK, Danielsson BRG, Marchner H, Lundin K Rundqvist E, Reiland S. Histopathological and hemodynamic, studies supporting hypoxia and vascular disruption as explanation to phenytoin teratogenicity. Teratology 1992; 46: 485-97.
25. Tiboni GM. Giampietro F. Di Giulio C. The nitric oxide synthesis inhibitor Nω-nitro-L-arginine methyl ester (L-NAME) causes limb defects in mouse fetuses: Protective effect of acute hyperoxia. Pediatr Res 2003; 54: 69-76.
26. Lam YH, Tang MH, Sin SY, Ghosh A, Lee CP. Limb reduction defects in fetuses with homozygous alpha-thalassacmia-1. Prenat Diagnosis 1997; 17: 1143-6.
27. Davies MP, An RH, Doevendans P, Kubalak S, ChienKR, Kass RS. Developmental changes in ionic channel activity in the embryonic murine heart. Circ Res 1996; 78: 15-25.
28. Wang L, Feng ZP, Kondo CS, Sheldon RS, Duff HJ. Developmental changes in the delayed rectifier K+ channels in mouse heart Circ Res 1996; 79: 79-85.
29. Franco D, Demolombe S, Kupershmidt S, Dumaine R, Dominguez JN, Roden D, et al. Divergent expression of delayed rectifier K(+) channel subunits during mouse heart development. Cardiovas Res 2001; 52: 65-75.
30. Langheinrich U, Vacun G. Wagner T. Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia. Toxicol Appl Pharmacol 2003; 193: 370-82.
31. Milan DJ, Peterson TA, Ruskin JN, Peterson RT, MacRae CA. Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation. 2003; 107: 1355-8.
32. He J-Q, Ma Y, Lee Y, Thomson JA, Kamp TJ. Human embryonic stem cells develop into multiple types of cardiac myocytes action potential characterization. Circ Res 2003; 93: 32-9.
33. Ban Y, Konishi R, Kawana K, Nakatsuka T, Fujii T, Manson JM. Embryotoxic effects of L-691,121, a class III antiarrhythmic agent, in rats. Arch Toxicol 1994; 69: 65-71.
34. Harris C. Hypoxia and altered redox status in embryotoxicity. In: Kavlock RJ and Daston GP, Eds. Drug toxicity in embryonic development I; advances in understanding mechanisms of birth efects: Mechanistic understanding of human developmental toxicants. Berlin: Springer Heidelberg 1997; p517-46.
35. Gibson JP, Huffman KW, Newbeme JW. Preclinical safety studies with terfenadine. Arzneimittel-Forschung/Drug Research 1982; 22: 1179-84.
36. Hourst Roussel Canada Inc 1992) Seldane product monograph. Hoescht Marion Roussel; 1992.
37. Whyatt PL. Astemizole in pregnancy. [Letter] Aust Fam Physician. 1986; 15: 382-4.
38. PDRρ entry for Hismanal (Janssen Pharmaceutica Inc) http://schoolasthmaallergy.com/html/medications/PackageInsert/ 40230100.HTM (July 3, 2007).
39. RxList - grepafloxacin http://www.rxlist.com/cgi/generic/ grepa_wch.htm (July 3, 2007).
40. FDA website-Raxar Grepafloxacin hydrochloride NDA 20-695 Pharmacology/ Toxicology Review. http://www.fda.gov/cder/foi/nda/97/ 20-695_Raxar_Pharma.pdf (July 3, 2007).
41. RxList-cisapride http://www.rxlist.com/cgi/generic/cisap_wcp_htm (July 3, 2007).
42. Skold AC, Danielsson C, Linder B, Danielsson BR. Teratogenicity of the I(Kr)-blocker cisapride: Relation to embryonic cardiac arrhythmia. Reprod Toxicol 2002; 16: 333-42.
43. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential? J Pharmacol Exp Ther 1997; 282: 220-7.
44. Funabashi H, Nishimura YC, Terada Y, Shigematsu K, Tateishi Y, Nakamura H. Reproductive and developmental toxicity studies of mosapride citrate. 2. Teratogenicity study in rats. Yakuri to Chiryo 1993; 21: 3423-45.
45. Funabashi H, Terada Y, Nakamura H, Matsuoka T, Takigaini H. Reproductive and developmental toxicity studies of mosapride cirate. 4. Teratogenicity study in rabbits. Yakuri to Chiryo 190; 21: 3469-79.
46. Taglialatela, M, Castaldo P, Pannaccione A, Giorgio G, Genovese A, Marone G, et al. Cardiac ion channels and antihistamines: Possible mechanisms of cardiotoxicity.Clin Exp Allergy 1999; 29 (Suppl 3): 182-9.
47. RxList - cetirizine - http://www.rxlist.com/cgi/generic/ cetiriz.wcp.htm (July 3,2007).
48. Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. J Clin Invest 2005; 115: 2025-32.
49. Witchel HJ, Pabbathi VK, Hofmann G, Paul AA, Hancox JC. Inhibitory actions of the selective serotonin re-uptake inhibitor citaloprain on HERG and ventricular L-type calcium currents.FEBS Lett 2002; 512: 59-66.
50. Fossa AA, Gorczyca W. Wisialowski T, Yasgar A, E, Crimin K, et al. Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antide-pressants. J Pharmacol Toxicol Methods 2007; 55: 78-85.
51. De Boer RA, van Dijk TH, Holman ND, van Melle JP. QT interval prolongation after sertraline overdose: A case report. BMC Emerg Med 2005; 5: 5.
52. Celexa (citalopram hydrobromide) pharmacological review part II. USFDA website. http://www.fda.gov/cder/foi/nda/98/020822a pharmr P2.pdf (July 3, 2007).
53. Prozac (Fluoxetine Hydrochloride) pharmacological review part II. US FDA website.http:/Www.fda.gov/cder/foi/nda/2003/ 18936S064_Prozac%20Pulvules_pharmr_P2.pdf (July 3, 2007).
54. NTP-CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Fluoxetine. April 2004, NTP-CERHR-04. http://cerhr.niehs.nih.gov/chemicals/fluoxetine/ fluoxetine_final.pdf (July 3, 2007).
55. Byrd RA, Markham JK. Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits. Fund Appl Toxicol 1994; 22: 511-8.
56. RxList fluoxetine HC1 - http://www.rxlist.com/cgi/generic/ fluoxetine.wcp.htm (July 3, 2007).
57. Stanford MS, Patton JH. In utero exposure to fluoxetine HC1 increases hematoma frequency at birth. Pharmacol Biochem Behav 1993; 45: 959-62
58. Teschemacher AG. Seward EP. Hancox JC. Witchel HJ. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol 1999; 128: 479-85.
59. Leonard HL, Meyer MC, Swede SE, Richter D, Hamburger SD, Allen AJ, et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiat 1995; 34:1460-6.
60. RxList Clomipramine HC1 -http://www.rxlist.com/cgi/generic/ lomipr_wcp.htm#P (July 3. 2007).
61. Product Proflle Clomicalm EMEA/V/C/039/01-03 http://www.emea.eu.int/ vetdocs/PDFs/EPAR/Clomicalm/006497en6.pdf (July 3, 2007).
62. RxList Imipramine - http://www.rxlist.com/cgi/generic/ imip_cp.htm#C (July 3, 2007).
63. RxList Venlafaxine hydrochloride - http://www.rxlist.com/cgi/ generic4/effex or wcp.htm (July 3, 2007).
64. Volberg WA, Koci BJ, Su W, Lin J, Zhou J. Blockade of human cardiac potassium channel human other-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther 2002; 302: 20-7.
65. RxList clarithromycin - http//www.rxlist.com/cgi/generic/ clarithwcp.htm (July 3, 2007).
66. Rulide and Rulide D, Approved Product Information, Aventis Pharma Pty Ltd, Australia. http://www.sanofi-aventis.com.au/products/ aus_pi_Rulide.pdf (July 3, 2007).
67. Ketek (Telithromycin) pharmacological review part http://www.fda.gov/ cder/foi/nda/2004/21-144_Ketek_Pharmr_P2.pdf) (July 3, 2007).
68. European Medicines Agency - Ketek-European Public Assessment Report, Part 6 Scientific Discussion. http://www.emea.eu.int/humandocs/ Humans/EPAR/ketek/ketek.htm (July 3, 2007).
69. RxList azithromycin - http://www.rxlist.com/cgi/generic4/ zmaxwcp.htm (July 3, 2007).
70. James WH. Are spontaneous abortion rates useful in monitoring reproductive hazards? Hum Reprod 1996; 11: 2333-5.
71. Bailey B, Addis A, Lee A, Sanghvi K, Mastroiacovo P, Mazzone T, et al. Cisapride use during human pregnancy: A prospective, controlled multicenter study. Dig Dis Sci 1997; 42: 1848-52.
72. Loebstein R, Lalkin A, Addis A, Costa A, Lalkin I, Bonati M, et al. Pregnancy outcome after gestational exposure to terfenadine: A multicenter, prospective controlled study. J Allergy Clin Immunol 1999; 104: 953-6.
73. Pastuszak A, Schick B, D'Alimonte D, Donnenfeld A, Koren G. The safety of astemizole in pregnancy. J Allergy Clin Immunol 1996; 98: 748-50
74. Kelso JM, Schatz M. Astemizole use in pregnancy. J Allergy Clin Immunol 1998; 101(1 Pt 1): 144.
75. Guidelines on risk assessment of medicinal products on human reproduction and lactation from data to labeling. EMEA/CHMP/2003927/2005.
76. Webster WS, Freeman JA. Is this drug safe in pregnancy? Reprod Toxicol 2001; 15: 619-29.
77. Czeizel AE. Rockenbauer M. Sorensen HT. Olsen J. A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol 1999; 13: 531-6.
78. Kallen BA, Otterblad Olausson P, Danielsson BR. Is erythromycin therapy teratogenic in humans? Reprod Toxicol 2005; 20: 209-14.
79. Kallen BA. Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003; 17: 255-61.
80. Danielsson BR, Azarbayjani F, Skold AC, Webster WS. 1997. Initiation of phenytoin teratogenesis: Pharmacologically induced embryonic bradycardia and arrhythmia resulting in bypoxia and possible free radical damage at reoxygenation. Teratology 56: 271-81.
81. Danielsson BR, Johansson A, Danielsson C, Azarbayjani F, Blomgren B, Skold AC. Phenytoin teratogenicity:hYpoxia marker and effects on embryonic heart rhythm suggest an hERG-related mechanism. Birth Defects Res (A Clin Mol Teratol) 2005; 73: 146-53.
82. Danielsson BR, Lansdell K, Patmore L, Tomson T. Phenytoin and phenobarbital inhibit human HERG potassium channels. Epilepsy Res 2003; 55: 147-157.
83. Donsky LV, Finnell RH. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: Epidemiologic and experimental findings spanning three decades; 2: Human studies. Reprod. Toxicol 1991; 5: 301-35.
84. Finnell RH, Dansky LV. Parental epilepsy. anticonvulsant drugs, and reproductive outcome: Epidemiologic and experimental findings spanning three decades; 1: Animal studies. Reprod Toxicol 1991; 5: 281-99.
85. Giles JJ, Bannigan JG. Teratogenic and developmental effects of lithium. Curr Pharm Des 2006; 12(12): 1531-41.
86. Thomas A Karle CA, Kiehn J. The cardiac hERG/IKr potassium channel as pharmacological target: Structure, function, regulation, and clinical applications. Curr Pharm Des 2006; 12(18): 2271-83.
87. Webster WS, Howe AM, Abela D, Oakes DJ. The relationship between cleft UP, maxillary hypoplasia, hypoxia and phenytoin. Curr Pharm Des 2006; 12(12): 1431-48.